Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD4 | P21917 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19659452 | 0.72 | RIPK1 (0.43) | ALOX15 | |
| SCHEMBL20939381 | 0.68 | NLRP3 (0.42) | ALOX15 | |
| SCHEMBL20861490 | 0.68 | DRD4 (0.37) | ALOX15DRD2DRD4DRD3CYP11B2 | |
| SCHEMBL23107185 | 0.68 | DRD4 (0.37) | ALOX15DRD2DRD4DRD3CYP11B2 | |
| SCHEMBL19029249 | 0.68 | PLK1 (0.36) | CYP11B2 | |
| SCHEMBL23107178 | 0.68 | DRD4 (0.37) | ALOX15DRD2DRD4DRD3CYP11B2 | |
| SCHEMBL17410066 | 0.67 | KDM4E (0.32) | — | |
| SCHEMBL20939184 | 0.64 | MAP3K14 (0.33) | — | |
| SCHEMBL24439795 | 0.63 | ALOX15 (0.33) | ALOX15 | |
| SCHEMBL23763318 | 0.63 | CYP11B1 (0.38) | ALOX15DRD2DRD4DRD3CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-30 | — | — | US | disclosed |
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032267-A1 | CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | MAP3K14, NFKBIA, MAP3K15 | ALOX15 1006/4885DRD2 4244/4885DRD4 4272/4885 |
| US-11186589-B2 | Cyanoindoline derivatives as NIK inhibitors | MAP3K14, NFKBIA, MAP3K15 | ALOX15 1006/4885DRD2 4244/4885DRD4 4272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.